You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

  1. A new radiopharmaceutical for the treatment of metastatic bone cancer

    SBC: IsoTherapeutics Group LLC            Topic: NCI

    DESCRIPTION provided by applicant There are roughly new cases of metastatic cancer to the skeleton in the U S each year andquot Bone seekingandquot radiopharmaceuticals are used for bone pain palliation and have shown promise for treating bone metastases They typically combine a radioactive metal such as samarium with a chelant The chelant part of the molecule is taken up by gr ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  2. Biomarker Quantitation by NP-MS Tissue Imaging.

    SBC: Ionwerks, Inc.            Topic: NIDA

    DESCRIPTION provided by applicant MALDI tissue imaging when enabled by Nanoparticulate NP Matrix implantation is maturing into a useful preclinical tool for biomarker and drug discovery in our laboratory and at NIDA IRP Quantitatively reproducible images from serial coronal sections suggest that relative quantitation is now possible in rodent models of disease and injury Nanoparticulate ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  3. Long-Acting G-CSF Analog for Treating ARS

    SBC: BOLDER BIOTECHNOLOGY INC            Topic: NIAID

    DESCRIPTION provided by applicant Development of radiological nuclear medical countermeasures to treat Acute Radiation Syndrome ARS is a high priority research area for NIAID Bone marrow is one of the most sensitive tissues to radiation damage and impaired hematopoiesis is one of the first clinical signs of excessive radiation exposure often resulting i death Granulocyte colony stimulating ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  4. Development of Inhaled Vancomycin for Treatment of MRSA Infections in CF

    SBC: SAVARA INC.            Topic: NHLBI

    DESCRIPTION provided by applicant Persistent respiratory methicillin resistant Staphylococcus aureus MRSA infections have become increasingly common in cystic fibrosis CF patients with a prevalence of almost in CF patients in the US This is concerning as MRSA positivity is associated with a faster decline of lung function and a years shorter median life expectancy compared to CF p ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government